179 related articles for article (PubMed ID: 21626050)
1. Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test.
Michael M; Cullinane C; Hatzimihalis A; O'Kane C; Milner A; Booth R; Schlicht S; Clarke SJ; Francis P
Cancer Chemother Pharmacol; 2012 Jan; 69(1):125-35. PubMed ID: 21626050
[TBL] [Abstract][Full Text] [Related]
2. Optimizing the erythromycin breath test for use in cancer patients.
Rivory LP; Slaviero K; Seale JP; Hoskins JM; Boyer M; Beale PJ; Millward MJ; Bishop JF; Clarke SJ
Clin Cancer Res; 2000 Sep; 6(9):3480-5. PubMed ID: 10999732
[TBL] [Abstract][Full Text] [Related]
3. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
Mathijssen RH; de Jong FA; van Schaik RH; Lepper ER; Friberg LE; Rietveld T; de Bruijn P; Graveland WJ; Figg WD; Verweij J; Sparreboom A
J Natl Cancer Inst; 2004 Nov; 96(21):1585-92. PubMed ID: 15523087
[TBL] [Abstract][Full Text] [Related]
4. The erythromycin breath test for the prediction of drug clearance.
Rivory LP; Slaviero KA; Hoskins JM; Clarke SJ
Clin Pharmacokinet; 2001; 40(3):151-8. PubMed ID: 11327195
[TBL] [Abstract][Full Text] [Related]
5. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.
Hirth J; Watkins PB; Strawderman M; Schott A; Bruno R; Baker LH
Clin Cancer Res; 2000 Apr; 6(4):1255-8. PubMed ID: 10778948
[TBL] [Abstract][Full Text] [Related]
6. Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol.
Yamamoto N; Tamura T; Murakami H; Shimoyama T; Nokihara H; Ueda Y; Sekine I; Kunitoh H; Ohe Y; Kodama T; Shimizu M; Nishio K; Ishizuka N; Saijo N
J Clin Oncol; 2005 Feb; 23(6):1061-9. PubMed ID: 15657405
[TBL] [Abstract][Full Text] [Related]
7. Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.
Engels FK; Mathot RA; Loos WJ; van Schaik RH; Verweij J
Cancer Biol Ther; 2006 Jul; 5(7):833-9. PubMed ID: 16775418
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer.
Slaviero KA; Clarke SJ; McLachlan AJ; Blair EY; Rivory LP
Br J Clin Pharmacol; 2004 Jan; 57(1):44-53. PubMed ID: 14678339
[TBL] [Abstract][Full Text] [Related]
9. In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil.
Krecic-Shepard ME; Barnas CR; Slimko J; Gorski JC; Wainer IW; Schwartz JB
Clin Pharmacol Ther; 1999 Jul; 66(1):40-50. PubMed ID: 10430108
[TBL] [Abstract][Full Text] [Related]
10. Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats.
Choi YH; Suh JH; Lee JH; Cho IH; Lee MG
J Pharm Pharmacol; 2010 Aug; 62(8):1084-8. PubMed ID: 20663044
[TBL] [Abstract][Full Text] [Related]
11. Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel.
Cox MC; Low J; Lee J; Walshe J; Denduluri N; Berman A; Permenter MG; Petros WP; Price DK; Figg WD; Sparreboom A; Swain SM
Clin Cancer Res; 2006 Aug; 12(15):4636-40. PubMed ID: 16899612
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin.
Paine MF; Wagner DA; Hoffmaster KA; Watkins PB
Clin Pharmacol Ther; 2002 Nov; 72(5):524-35. PubMed ID: 12426516
[TBL] [Abstract][Full Text] [Related]
13. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer.
Koolen SL; Oostendorp RL; Beijnen JH; Schellens JH; Huitema AD
Br J Clin Pharmacol; 2010 May; 69(5):465-74. PubMed ID: 20573082
[TBL] [Abstract][Full Text] [Related]
15. 4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.
de Graan AJ; Sparreboom A; de Bruijn P; de Jonge E; van der Holt B; Wiemer EA; Verweij J; Mathijssen RH; van Schaik RH
Br J Clin Pharmacol; 2015 Sep; 80(3):560-8. PubMed ID: 26119961
[TBL] [Abstract][Full Text] [Related]
16. Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.
Baririan N; Van Obbergh L; Desager JP; Verbeeck RK; Wallemacq P; Starkel P; Horsmans Y
Clin Pharmacokinet; 2007; 46(3):261-70. PubMed ID: 17328584
[TBL] [Abstract][Full Text] [Related]
17. Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?
Wanwimolruk S; Paine MF; Pusek SN; Watkins PB
Br J Clin Pharmacol; 2002 Dec; 54(6):643-51. PubMed ID: 12492613
[TBL] [Abstract][Full Text] [Related]
18. Effect of mibefradil on CYP3A4 in vivo.
Veronese ML; Gillen LP; Dorval EP; Hauck WW; Waldman SA; Greenberg HE
J Clin Pharmacol; 2003 Oct; 43(10):1091-100. PubMed ID: 14517191
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.
Yong WP; Wang LZ; Tham LS; Wong CI; Lee SC; Soo R; Sukri N; Lee HS; Goh BC
Cancer Chemother Pharmacol; 2008 Jul; 62(2):243-51. PubMed ID: 17909805
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms.
Tran A; Jullien V; Alexandre J; Rey E; Rabillon F; Girre V; Dieras V; Pons G; Goldwasser F; Tréluyer JM
Clin Pharmacol Ther; 2006 Jun; 79(6):570-80. PubMed ID: 16765145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]